Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranilast as a Radiosensitizer in Recurrent Nasopharyngeal Carcinoma
NCT05626829Phase 2Unknown
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tranilast in nasopharyngeal carcinoma (NPC). Primary endpoint: Effectiveness of Tranilast in reradiation of recurrent nasopharyngeal carcinoma at 12 weeks. Status: unknown.
02
Drugs
tranilast
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05626829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626829.